Glutathione-Responsive Tannic Acid-Assisted FRET Nanomedicine for Cancer Therapy.

FRET camptothecin combination cancer therapy curcumin glutathione-responsive nanoparticle tannic acid

Journal

Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003

Informations de publication

Date de publication:
24 Apr 2023
Historique:
received: 17 02 2023
revised: 03 04 2023
accepted: 05 04 2023
medline: 27 5 2023
pubmed: 27 5 2023
entrez: 27 5 2023
Statut: epublish

Résumé

In cancer combination therapy, a multimodal delivery vector is used to improve the bioavailability of multiple anti-cancer hydrophobic drugs. Further, targeted delivery of therapeutics along with simultaneous monitoring of the drug release at the tumor site without normal organ toxicity is an emerging and effective strategy for cancer treatment. However, the lack of a smart nano-delivery system limits the application of this therapeutic strategy. To overcome this issue, a PEGylated dual drug, conjugated amphiphilic polymer (CPT-S-S-PEG-CUR), has been successfully synthesized by conjugating two hydrophobic fluorescent anti-cancer drugs, curcumin (CUR) and camptothecin (CPT), through an ester and a redox-sensitive disulfide (-S-S-) linkage, respectively, with a PEG chain via in situ two-step reactions. CPT-S-S-PEG-CUR is spontaneously self-assembled in the presence of tannic acid (TA, a physical crosslinker) into anionic, comparatively smaller-sized (~100 nm), stable nano-assemblies in water in comparison to only polymer due to stronger H-bond formation between polymer and TA. Further, due to the spectral overlap between CPT and CUR and a stable, smaller nano-assembly formation by the pro-drug polymer in water in presence of TA, a successful Fluorescence Resonance Energy Transfer (FRET) signal was generated between the conjugated CPT (FRET donor) and conjugated CUR (FRET acceptor). Interestingly, these stable nano-assemblies showed a preferential breakdown and release of CPT in a tumor-relevant redox environment (in the presence of 50 mM glutathione), leading to the disappearance of the FRET signal. These nano-assemblies exhibited a successful cellular uptake by the cancer cells and an enhanced antiproliferative effect in comparison to the individual drugs in cancer cells (AsPC1 and SW480). Such promising in vitro results with a novel redox-responsive, dual-drug conjugated, FRET pair-based nanosized multimodal delivery vector can be highly useful as an advanced theranostic system towards effective cancer treatment.

Identifiants

pubmed: 37242568
pii: pharmaceutics15051326
doi: 10.3390/pharmaceutics15051326
pmc: PMC10222396
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : NIH HHS
ID : CA210192, CA206069, and GM139727
Pays : United States

Références

J Mater Chem B. 2015 Oct 21;3(39):7724-7733
pubmed: 26617985
Pharmacol Res. 2019 Jan;139:91-105
pubmed: 30408575
J Am Chem Soc. 2006 Aug 16;128(32):10378-9
pubmed: 16895398
Macromol Biosci. 2017 Apr;17(4):
pubmed: 27879056
Cells. 2019 Dec 31;9(1):
pubmed: 31906106
Bioorg Med Chem. 1998 May;6(5):551-62
pubmed: 9629468
Pharmaceutics. 2022 Feb 18;14(2):
pubmed: 35214171
ACS Appl Mater Interfaces. 2020 Feb 12;12(6):7466-7476
pubmed: 31958004
Biomaterials. 2019 Jul;208:83-97
pubmed: 30999154
J Control Release. 2017 Jul 10;257:76-83
pubmed: 27677603
Drug Resist Updat. 2021 Sep;58:100777
pubmed: 34481195
Chem Rev. 2017 Nov 22;117(22):13566-13638
pubmed: 29048884
Nanoscale. 2019 Nov 14;11(42):20058-20071
pubmed: 31612185
J Agric Food Chem. 2011 Feb 9;59(3):1012-9
pubmed: 21204534
J Am Chem Soc. 2013 Feb 27;135(8):2907-10
pubmed: 23379791
Bioconjug Chem. 2015 Dec 16;26(12):2497-506
pubmed: 26497258
J Pharm Biomed Anal. 1997 Aug;15(12):1867-76
pubmed: 9278892
Int J Nanomedicine. 2012;7:1761-79
pubmed: 22619526
J Am Chem Soc. 2014 Aug 20;136(33):11748-56
pubmed: 25078892
Sci Rep. 2018 Jun 20;8(1):9410
pubmed: 29925967
Nanoscale. 2020 Aug 20;12(32):16710-16715
pubmed: 32785392
J Colloid Interface Sci. 2019 Feb 1;535:133-148
pubmed: 30292104
ACS Appl Mater Interfaces. 2016 Oct 12;8(40):27199-27206
pubmed: 27648478
Nanomaterials (Basel). 2019 Apr 26;9(5):
pubmed: 31035517
Adv Drug Deliv Rev. 2019 Mar 15;143:177-205
pubmed: 31201837
Eur J Pharm Biopharm. 2021 Jun;163:72-101
pubmed: 33774162
Nucleic Acids Res. 2010 Jul;38(Web Server issue):W609-14
pubmed: 20430828
Nat Mater. 2013 Nov;12(11):991-1003
pubmed: 24150417
Sci Rep. 2016 Feb 03;6:20051
pubmed: 26837852
Nanoscale Adv. 2021 Sep 1;3(21):6007-6026
pubmed: 34765868
Bioact Mater. 2021 Jan 23;6(8):2291-2302
pubmed: 33553816
Langmuir. 2020 Mar 10;36(9):2383-2395
pubmed: 32036662
ACS Appl Mater Interfaces. 2019 Oct 23;11(42):38537-38554
pubmed: 31553876
Chem Commun (Camb). 2018 Oct 11;54(82):11618-11621
pubmed: 30264076
ACS Appl Mater Interfaces. 2017 Oct 11;9(40):34650-34665
pubmed: 28920426
Anticancer Drugs. 2009 Jul;20(6):444-9
pubmed: 19384191
Polymers (Basel). 2019 Apr 27;11(5):
pubmed: 31035564
Sci Rep. 2020 Jul 21;10(1):12045
pubmed: 32694520
Mol Pharm. 2007 Nov-Dec;4(6):807-18
pubmed: 17999464
Nanoscale. 2019 Mar 14;11(11):4751-4758
pubmed: 30601558
Adv Healthc Mater. 2018 Jan;7(1):
pubmed: 28941203
ACS Appl Mater Interfaces. 2020 Mar 4;12(9):10959-10972
pubmed: 32026696
Nat Commun. 2018 Jul 17;9(1):2785
pubmed: 30018290
Molecules. 2019 Jul 10;24(14):
pubmed: 31295906
J Colloid Interface Sci. 2014 Sep 15;430:305-14
pubmed: 24974243
Drug Discov Today. 2016 Jul;21(7):1189-95
pubmed: 27240777
Biomater Sci. 2021 Feb 21;9(4):1431-1448
pubmed: 33404026
Int J Oncol. 2018 Sep;53(3):1343-1353
pubmed: 29956726
Theranostics. 2020 Mar 15;10(10):4557-4588
pubmed: 32292515
Clin Cancer Res. 2008 Mar 15;14(6):1888-96
pubmed: 18347192
Cancers (Basel). 2018 Mar 07;10(3):
pubmed: 29518944
Genes (Basel). 2019 Jul 26;10(8):
pubmed: 31357510
J Gastroenterol. 2014 Oct;49(10):1378-91
pubmed: 24097071
Mol Pharm. 2004 Sep-Oct;1(5):375-82
pubmed: 16026008
Pharmaceutics. 2021 Sep 13;13(9):
pubmed: 34575537
Adv Mater. 2021 Dec;33(48):e2104223
pubmed: 34580933
J Mater Chem B. 2015 Feb 7;3(5):824-833
pubmed: 32262173
Bioconjug Chem. 2004 Nov-Dec;15(6):1364-75
pubmed: 15546204
Nanoscale. 2018 Dec 28;10(48):22830-22847
pubmed: 30488937
ACS Nano. 2023 Jan 9;:
pubmed: 36623255
Chem Commun (Camb). 2011 Aug 14;47(30):8647-9
pubmed: 21725532
J Colloid Interface Sci. 2017 Sep 1;501:22-33
pubmed: 28432913
ACS Appl Mater Interfaces. 2019 Jul 10;11(27):23840-23847
pubmed: 31251019
Nano Today. 2016 Feb;11(1):13-30
pubmed: 27066106
Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):113-25
pubmed: 20456930
Colloids Surf B Biointerfaces. 2016 Mar 1;139:107-16
pubmed: 26704991
ACS Appl Mater Interfaces. 2022 Jan 19;14(2):2650-2662
pubmed: 34995459

Auteurs

Partha Laskar (P)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
The Ångström Laboratory, Macromolecular Chemistry, Department of Chemistry, Uppsala University, 751 21 Uppsala, Sweden.

Anupam Dhasmana (A)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
Cancer Research Institute, Himalayan School of Biosciences, Swami Rama Himalayan University, Dehradun 248016, India.

Sudhir Kotnala (S)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.

Meena Jaggi (M)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.

Murali M Yallapu (MM)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.

Subhash C Chauhan (SC)

Department of Immunology and Microbiology, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.
South Texas Center of Excellence in Cancer Research, School of Medicine, University of Texas Rio Grande Valley, McAllen, TX 78504, USA.

Classifications MeSH